GeneMe Limited, a biotechnology company based in Poland that performs genetic testing in their own laboratories using the most efficient molecular biology techniques and genetic engineering methodologies, announced securing €5.2 million seed funding on 17th December 2020.
This funding round was led by Robin Tombs, the co-founder of the digital identity platform Yoti, and earlier the software dev and gaming enterprise, Gamesys Group, joined by a few other angel investors.
The company is focused on several products and services in the field of polymorphism analysis and defining the genetic tests broadly. Presently they offer research on SNPs that affect the body functions, food intolerances, oncological risks, diseases and sports predispositions.
Geneme have several departments however the prime ones are the research laboratory and a development one. They offer testing services but they constantly focus on the R&D for developing new products, services and methods for genetic testing.
Recently Geneme developed a universal protein named polymerase for testing RT-LAMP, that produces rapid, molecular and accurate genetic COVID tests. There are three molecular NAAT COVID tests, FRANKD, ICED AND SAVD. Among these, FRANKD is a CE IV approved test with FDA EUA applied with its solutions already being used in around twenty countries. Through the official research done by the Scottish government, FRANKD is identified as the most rapid and accurate test for covid-19 present in the market. The test has already been used by Virgin Atlantic, Heathrow airport and a television show Britain’s Got Talent.
This technology makes the testing easier as compared to the laboratory based RT PCR tests. Since, RT-LAMP tests are more accurate, their results are trustworthy.
Robin Tombs, Yoti co- founder and the lead investor of the seed funding round said, “The innovative approach of Geneme will be quite disruptive in the coming time, and help regular testing to reach at the point of care and low cost.”
Their testing technology can be enabled to the point of care making it possible for integrating in highly precise testing stations at workplaces and the high throughput locations like the international borders.
Recently Geneme also announced a partnership with, BIOLYPH the US based world leader of lyophilization services for scaling its COVID-19 tests FRANKD and SAVD. They are conducting innovative and advanced work for the global scale technologies, nucleic acid amplification on the bases of isothermal amplification reaction for implementing this technology in the RNA analysis and mutation diagnostics. This approach is carried forward with the aim of taking the right advantage of nucleic acid analysis based diagnostic methods, and rapid and mobility for the protein and antibodies based detection methods.
We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
